Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Pfizers exit and repercussions With the backing of Pfizer and the promising early human data, MetaBio could have been a big player in developing a new therapeutic for diabetes
Diabetes Obes Metab 23(3):754762 Vilsbll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
Clinical trials are testing for these effects, with early results indicating better blood sugar control and the potential to reduce the need for other diabetes drugs
Calorie restriction with or without time-restricted eating in weight loss
US$ 23.32
US$ 22.44
US$ 25.17
US$ 29.52
US$ 28.55
US$ 20.28
US$ 22.27
